Summary of COVID-19 SIR1-365 studies

1. Qu et al., A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19

45 patient SIR1-365 late treatment RCT: 88% worse recovery (p=0.44).
Pilot RCT 42 hospitalized COVID-19 patients showing no significant differences with SIR1-365 treatment. foo
Nov 2021, NCT04622332, https://clinicaltrials.gov/study/NCT04622332, https://c19p.org/qu3